KEY DETAILS
The FutureShape Family trial, sponsored by Signe Torekov, is not yet recruiting. ClinicalTrials.gov lists a start date of October 1, 2026 and a completion date of January 31, 2031.
A preprint posted on medRxiv, not yet peer reviewed, found GLP-1 receptor agonists and SGLT2 inhibitors had no detectable effect on osteoarthritis-related serious adverse events over about two years.
A Lancet Psychiatry observational cohort study found GLP-1 therapy initiation was associated with lower psychiatric acute-care use in adults with schizophrenia and type 2 diabetes.
Three items touching GLP-1 research are covered here, from a trial that is not yet recruiting to a study on mental health outcomes. If you take or are considering a GLP-1 medication, these updates show what each item reports and what it does not.
The FutureShape Family trial, sponsored by Signe Torekov, is listed as Phase 4 and is not yet recruiting participants. ClinicalTrials.gov lists a start date of October 1, 2026 and a completion date of January 31, 2031. The trial is registered under NCT07872904 and lists obesity and overweight as its conditions. Interventions listed are family care, standard care, semaglutide (administered by PDS290 pen-injector) and placebo (administered by PDS290 pen-injector). Enrollment is listed as 400. So there is nothing to report yet beyond the registration itself.
A preprint posted on medRxiv looked at whether drugs proposed to protect or harm joints change serious osteoarthritis events, drawing on adverse event tables from 881 randomized trials. It found that GLP-1 receptor agonists and SGLT2 inhibitors had no detectable effect on osteoarthritis-related serious adverse events over about two years, in trials that detected their known effects. The preprint says slow or modest structural effects remain possible, and the paper has not been peer reviewed.
An observational cohort study in The Lancet Psychiatry, using electronic health records data from the USA, followed adults with schizophrenia and type 2 diabetes. It found that starting GLP-1 therapy was associated with lower psychiatric acute-care use than not starting it or starting a DPP-4 or SGLT2 inhibitor. The study notes that potential residual confounding and selection bias restrict how broadly the results can be applied.
These three items are different kinds of evidence: a trial registration with no results, a preprint that has not been peer reviewed, and an observational study that shows an association rather than a cause.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.